Patents by Inventor Didier Wirth

Didier Wirth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 4761495
    Abstract: The present invention is directed to a composition and method relating to the preparation of aspartyl peptides having the general formula: ##STR1## where the radical-NHR represents an amino acid or peptide group. In the method, a .beta.-monoester of aspartic acid having the general formula: ##STR2## where R.sub.1 represents a hydrocarbon-containing radical, is reacted with a .beta.-dicarbonyl compound, preferably ethylacetoacetate to protect the aspartyl amino group and form an enamine. The enamine is then coupld to an amino acid or peptide, following which any protecting groups are removed to yield .alpha.-aspartyl peptides without any .beta.-isomer. In its composition aspects, the present invention is directed to novel enamines resulting from reaction of the .beta.-monoester of aspartic acid with a .beta.-dicarbonyl compound.
    Type: Grant
    Filed: January 11, 1985
    Date of Patent: August 2, 1988
    Assignee: Isochem S.A.
    Inventors: Didier Wirth, Dominique Gibert, Annie Boutin
  • Patent number: 3987042
    Abstract: Phenothiazine derivatives are described of the formula ##SPC1##In which X.sub.1 and X.sub.2, which may be the same or different, are H, R, F, Cl, Br, OR, CN, --COR, CH.sub.3, --S--R, --SOR, --SO.sub.2 R or --SO.sub.2 N(CH.sub.3).sub.2, where R is an alkyl group having from 1 to 4 carbon atoms, and the quinuclidine ring is substituted by the group --(CH.sub.2).sub.x -- in the 2- or 3- position, x being 1 or 2 when said group is substituted in the 2-position and being 0 or 1 when said group is substituted in the 3-position (because of electronic hindrance), and their acid addition and quaternary ammonium salts, have valuable pharmacological properties. In particular, these compounds have anti-histaminic, anti-cholinergic, adrenolytic, neuro-sedative, tranquillizing and/or spasmolytic properties.These compounds are prepared by condensing an appropriate phenothiazine with a quinuclidine derivative of the formula ##SPC2##In which x has the above-stated meaning and Z is a halogen atom or a reactive ester group.
    Type: Grant
    Filed: October 10, 1975
    Date of Patent: October 19, 1976
    Inventors: Claude Gueremy, Robert Labey, Didier Wirth, Maurice Auclair